Akorn gets FDA nod for betamethasone dipropionate

Akorn, a leading specialty pharmaceutical company, has received the Food and Drug Administration’s clearance for betamethasone dipropionate lotion (augmented), 0.05%.

Betamethasone dipropionate lotion (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older.

Betamethasone dipropionate lotion (augmented), 0.05% had a market value of approximately $10 million for the 12 months ended August 2019, according to IQVIA.

The product is manufactured at Akorn’s Amityville, N.Y. manufacturing facility.